Guidance. Clarity. Direction.

Carter, DeLuca & Farrell LLP, a leader in intellectual property law, provides cost-effective services to clients from around the world, protecting innovations in a wide range of technologies.

Throughout the phases of product or brand development, we form a critical part of our clients’ development teams to provide preparation, prosecution and clearance services to maximize protection while navigating through freedom-to-operate challenges. We also provide extensive IP due diligence services and IP asset assimilation to help our clients achieve their business objectives.

Search Attorneys

Events

Check back for future events

CAFC Update

NUVO PHARMACEUTICALS v. DR. REDDY’S LABORATORIES INC. May 15, 2019

Nuvo sued three Generics manufacturers (Dr. Reddy’s Laboratories, Mylan Pharmaceuticals, and Lupin Pharmaceuticals) to prevent their ANDA products from going to market, if approved, before the expiration of U.S. Patent Nos. 6,926,907 and 8,557,285, relating to the coordinated the release of an acid inhibitor (such as proton pump inhibitors (“PPIs”) like omeprazole and esomeprazole) and an NSAID...

Nuvo sued three Generics manufacturers (Dr. Reddy’s Laboratories, Mylan Pharmaceuticals, and Lupin Pharmaceuticals) to prevent their ANDA products from going to market, if...

BTG INTERNATIONAL LIMITED v. AMNEAL PHARMACEUTICALS LLC May 14, 2019

BTG sued Amneal Pharmaceuticals, asserting that Amneal’s Abbreviated New Drug Applications (“ANDA”) for the generic version of BTG’s abiraterone product ZYTIGA® infringes U.S. Patent No. 8,822,438 relating to methods and compositions for treating cancer by administering a CYP17 inhibitor in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Subsequently, Amerigen,...

BTG sued Amneal Pharmaceuticals, asserting that Amneal’s Abbreviated New Drug Applications (“ANDA”) for the generic version of BTG’s abiraterone product ZYTIGA® infringes U.S. Patent...

NOVARTIS PHARMACEUTICALS CORP v. WEST-WARD PHARMACEUTICALS May 13, 2019

West-Ward Pharmaceuticals appeals the decision of the District Court holding that claims of U.S. Patent No. 8,410,131 which claims methods of using the compound everolimus (an mTOR inhibitor and the active ingredient in Novartis’s Afinitor product) to treat advanced renal cell carcinoma (“RCC”), would not have been obvious in view of the prior art. The CAFC

West-Ward Pharmaceuticals appeals the decision of the District Court holding that claims of U.S. Patent No. 8,410,131 which claims methods of using the...